Seeking Alpha

Flamel Technologies (FLML) has had a string of rather good news. It recently received FDA approval for its drug Bloxiverz. What is even better is the fact that Flamel already has a rather substantial amount of income coming in for a small-cap stock. With all of this good news, there is still a large amount of upside potential left for this stock. The one main problem with Flamel Technologies is in the fact that it is hesitant to report key information about its drugs in development. This makes planning for the long term to be much more of a guessing game than usual (which is already a huge guessing game). However, this represents interesting catalysts depending on...

Only subscribers can access this article, which is part of the PRO research library covering 3,775 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: